Fiche société
Merck Sharp & Dohme LLC
Traitements, essais et publications liés.
Traitements103programmes
Essais48liés
Publications144liées
SourceDBlocale
Traitements
103| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 5-Fluorouracil (5-FU)This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| 5-FUThe study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, … | À vérifier |
| 5-hydroxytryptamine subtype 3 receptor antagonistResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| Abiraterone acetateThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| ATRASubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, France, Israel, Italy, South Africa, Switzerland | À vérifier |
| BelzutifanThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, … | À vérifier |
| Blood Sample CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| BoserolimabThe purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study. | Parkinson | Phase 1/2 | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| CalderasibThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, … | À vérifier |
| CapecitabineThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, … | À vérifier |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Cisplatin 100 mg/m^2This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| corticosteroidThe goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus, Parkinson | Phase 2 | À vérifier | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| DocetaxelDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| DocetetaxelResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| DoxorubicinThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS). | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| EnzalutamideThis study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| Etoposide 100 mg/m^2Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Fludrocortisone acetateThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| HER3-DXdThis is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| HydrocortisoneThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| Ifinatamab DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| IrinotecanThe irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with 1-year survival rate of 64.2%. Again, the investigators showed that the second-line Irinotecan and cisplatin is an active and well-tolerated regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in blood via metabolism by liver enzyme, and 5-chloro-2, 4-dihydroxypyridine enhance the serum concentration of 5-FU by the competitive inhibition of dihydropyrimidine dehydrogenase, an enzyme responsible for 5-FU catabolism. Potassium oxonate is also a reversible competitive inhibitor of orotate phosphoribosyl transferase, a phosphoenzyme for 5-FU. Diarrhea induced by 5-FU administration is though to be attributable to the phosphorylation of 5-FU by the enzyme in the gastrointestinal tissue. After oral administration of potassium oxonate, the concentration of potassium in the gastrointestinal tissue is high enough to inhibit the enzyme while the concentration in blood and tumor is reported to be either slight or nil. Because of these mechanism, oral TS-1 administration generates a higher concentration of 5-FU than protracted intravenous infusion of 5-FU given in a dose equimolar to the tegafur in S-1, whereas the incidence of adverse events concerning the GI tract does not increase. In a phase II trial of TS-1 as first-line setting in NSCLC, the response rate was 22% and the median survival time was 10.2 months. As expected, the incidence of severe gastrointestinal adverse events was low, and so was few severe hematologic toxicity. Recently 3-weekly TS-1 plus cisplatin showed activity against NSCLC with a response rate of 32.7% and the safety was acceptable. | Cancer, Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, … | À vérifier |
| LenvatinibThe purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS). Based on recommendation of the external Data Monitoring Committee (eDMC), Amendment 3 (effective: September \[Sep\]-24-2021) was implemented to unblind the study and discontinue lenvatinib and placebo treatment. The eDMC was then disbanded. With Amendment 4 (effective: December-5-2022) second course pembrolizumab will no longer be offered. Any participant receiving second course pembrolizumab treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. Study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, Colombia, Denmark, France, … | À vérifier |
| LevoleucovorinThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| liposomal doxorubicinThis phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. | Cancer, Parkinson | Phase 3 | Thérapie cellulaire | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, … | À vérifier |
| MK-0472The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer, Lupus | Phase 1 | À vérifier | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, … | À vérifier |
| MK-1084The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| MK-1484The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Israel, Netherlands | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| MK-4830The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, … | À vérifier |
| MK-6194The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, France, … | À vérifier |
| Nab-paclitaxelThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1). | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Neurokinin-1 receptor antagonistResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| olaparibBackground: EP0057 (formerly CRLX101) consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood. Once inside cancer cells, the chemotherapy drug is released from the molecule. Olaparib is a drug that may stop cancer cells from repairing the deoxyribonucleic acid (DNA) damage caused by chemotherapy. Researchers want to see how safe it is to give EP0057 and olaparib together and to see how well the combination treats a specific type of lung cancer called small cell lung cancer (SCLC). Objectives: To test the safety and maximum dose of EP0057 and olaparib together. To test how well they treat small cell lung cancer. Eligibility: Adults 18 and older with small cell lung cancer. Design: Participants will be screened with standard cancer care tests. Participants will get the 2 study drugs in 28-day cycles. EP0057 will be given every 2 weeks, through a small plastic tube in an arm vein. Olaparib will be taken by mouth twice a day most days. Participants will keep a pill diary. For Cycle 1, participants will have 3 visits. All other cycles will have 2 visits. At study visits, participants may have: * Blood and hair samples taken * History and Physical exam * Questions about health and side effects * Pregnancy test * Optional tumor biopsy where a piece of tumor is removed by needle after numbing the skin. * Computed tomography (CT) scan * Injection of EP0057 (twice per cycle) * Olaparib prescription Participants will have a follow-up visit 4 weeks after finish taking the drugs. They will have a physical exam and blood tests. They may have a tumor biopsy. The study team will call the patient every 3 months for follow up after completing the study treatment. | Cancer, Parkinson | Phase 2 | À vérifier | United States, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, … | À vérifier |
| Olaparib 300 mg BIDResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Pembrolizumab 400 mgResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Pembrolizumab/QuavonlimabThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, … | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Platinum, investigator's choiceResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Prednisone acetateThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, … | À vérifier |
| QuavonlimabSubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, France, Israel, Italy, South Africa, Switzerland | À vérifier |
| R-DXdResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer | Phase 3 | À vérifier | À vérifier | |
| Radiotherapy 60 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Radiotherapy 66 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Radiotherapy 70 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Raludotatug DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| Rescue MedicationResearchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Rescue MedicationsResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer, Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| Rescue medications for chemotherapyResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| Rescue medications for sacituzumab tirumotecanResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| Rituximab biosimilarResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy) | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Israel, Spain, Taiwan, Turkey (Türkiye) | À vérifier |
| S-1The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Sacituzumab Tirumotecan (sac-TMT)This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| Standard Thoracic RadiotherapyResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Supportive care measuresThis is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, … | À vérifier |
| TACEThe purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS). | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, Colombia, Denmark, France, … | À vérifier |
| TelcagepantThe purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Telcagepant 140 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| Telcagepant 280 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| Tumor Tissue CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| VibostolimabSubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| VinflunineResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| liposomal doxorubicinThis phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. | Cancer | Phase 2 | Thérapie cellulaire | United States | À vérifier |
| TelcagepantThe purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Telcagepant 140 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| IrinotecanThe irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with 1-year survival rate of 64.2%. Again, the investigators showed that the second-line Irinotecan and cisplatin is an active and well-tolerated regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in blood via metabolism by liver enzyme, and 5-chloro-2, 4-dihydroxypyridine enhance the serum concentration of 5-FU by the competitive inhibition of dihydropyrimidine dehydrogenase, an enzyme responsible for 5-FU catabolism. Potassium oxonate is also a reversible competitive inhibitor of orotate phosphoribosyl transferase, a phosphoenzyme for 5-FU. Diarrhea induced by 5-FU administration is though to be attributable to the phosphorylation of 5-FU by the enzyme in the gastrointestinal tissue. After oral administration of potassium oxonate, the concentration of potassium in the gastrointestinal tissue is high enough to inhibit the enzyme while the concentration in blood and tumor is reported to be either slight or nil. Because of these mechanism, oral TS-1 administration generates a higher concentration of 5-FU than protracted intravenous infusion of 5-FU given in a dose equimolar to the tegafur in S-1, whereas the incidence of adverse events concerning the GI tract does not increase. In a phase II trial of TS-1 as first-line setting in NSCLC, the response rate was 22% and the median survival time was 10.2 months. As expected, the incidence of severe gastrointestinal adverse events was low, and so was few severe hematologic toxicity. Recently 3-weekly TS-1 plus cisplatin showed activity against NSCLC with a response rate of 32.7% and the safety was acceptable. | Cancer | Phase 1 | À vérifier | South Korea | À vérifier |
| MK-1484The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Israel, Netherlands | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czechia, Estonia, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, … | À vérifier |
| MK-6194The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, France, Guatemala, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Spain, Turkey (Türkiye) | À vérifier |
| MK-0472The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Israel, Italy, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 1 | À vérifier | Japan | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Lupus | Phase 1 | À vérifier | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, Peru, Romania, Thailand | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, … | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 2 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Japan, Netherlands, Singapore, South Korea, Spain, United Kingdom | À vérifier |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Israel, Spain, Taiwan, Turkey (Türkiye) | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, Greece, Israel, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, … | À vérifier |
| Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Israel, Japan, Poland, Portugal, Russia, South Korea, Spain, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Japan, Norway, … | À vérifier |
| HydrocortisoneThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| Raludotatug DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Tumor Tissue CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, Ukraine | À vérifier |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, Singapore, South Korea, Switzerland, Taiwan, Thailand, Turkey (Türkiye) | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Chile, China, Costa Rica, Czechia, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Malaysia, Mexico, Philippines, Portugal, Romania, … | À vérifier |
| R-DXdResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer | Phase 3 | À vérifier | À vérifier | |
| LenvatinibThe purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS). Based on recommendation of the external Data Monitoring Committee (eDMC), Amendment 3 (effective: September \[Sep\]-24-2021) was implemented to unblind the study and discontinue lenvatinib and placebo treatment. The eDMC was then disbanded. With Amendment 4 (effective: December-5-2022) second course pembrolizumab will no longer be offered. Any participant receiving second course pembrolizumab treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. Study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Peru, Poland, Portugal, South Korea, … | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, … | À vérifier |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, Greece, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Russia, Serbia, South Africa, … | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, New Zealand, Poland, South Africa, … | À vérifier |
| CalderasibThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, France, Georgia, Germany, Greece, India, Italy, Japan, Mexico, Netherlands, New Zealand, Philippines, … | À vérifier |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
48| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab | Parkinson | Phase 2 | NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | TERMINATED |
| carboplatin | Cancer | Phase 2 | NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Calderasib | Parkinson | Phase 3 | NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING |
| pembrolizumab/vibostolimab | Parkinson | Phase 3 | NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | TERMINATED |
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | ACTIVE_NOT_RECRUITING |
| paclitaxel | Cancer | Phase 2 | NCT06245889 | NeoADAPT — PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | RECRUITING |
| Opevesostat | Cancer | Phase 3 | NCT06136624 | OMAHA-003 — Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | RECRUITING |
| MK-2214 | Alzheimer | Phase 1 | NCT05466422 | A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) | COMPLETED |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06170788 | TroFuse-007 — Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | RECRUITING |
| Ramucirumab | Parkinson | Phase 1/2 | NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | RECRUITING |
| Lenvatinib | Cancer | Phase 3 | NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | TERMINATED |
| R-DXd | Cancer | Phase 3 | NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) | NOT_YET_RECRUITING |
| pembrolizumab/vibostolimab | Parkinson | Phase 3 | NCT05298423 | KEYVIBE-006 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | RECRUITING |
| paclitaxel | Parkinson | Phase 1/2 | NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | RECRUITING |
| Tumor Tissue Collection | Parkinson | À vérifier | NCT04165798 | KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | RECRUITING |
| Raludotatug Deruxtecan | Parkinson | Phase 2 | NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | COMPLETED |
| Hydrocortisone | Cancer | Phase 2 | NCT07763210 | Lazarus: IT Therapy for ICANS | NOT_YET_RECRUITING |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT07318558 | TroFuse-021 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | RECRUITING |
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | ACTIVE_NOT_RECRUITING |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT06312137 | TroFuse-019 — A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | RECRUITING |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT07419295 | TroFuse-031 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | RECRUITING |
| MK-1045 | Cancer | Phase 2/3 | NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | RECRUITING |
| carboplatin | Cancer | Phase 2 | NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | RECRUITING |
| MK-2214 | Alzheimer | Phase 2 | NCT07033494 | A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING |
| MK-1045 | Lupus | Phase 1 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 1 | NCT06049212 | TroFuse-008 — Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | ACTIVE_NOT_RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | RECRUITING |
| MK-0472 | Parkinson | Phase 1 | NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | RECRUITING |
| MK-6194 | Lupus | Phase 2 | NCT06161116 | Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) | TERMINATED |
| Opevesostat | Cancer | Phase 3 | NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | RECRUITING |
| MK-1484 | Parkinson | Phase 1 | NCT05382325 | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | COMPLETED |
| Irinotecan | Cancer | Phase 1 | NCT00874328 | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | UNKNOWN |
| Telcagepant 140 mg | Migraine | Phase 2 | NCT00797667 | MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) | TERMINATED |
| Telcagepant | Migraine | Phase 3 | NCT00662818 | Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 3 | NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | COMPLETED |
| liposomal doxorubicin | Cancer | Phase 2 | NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | TERMINATED |
Publications
144| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Radiotherapy 70 Gray | Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC. | Clinical cancer research : an official journal of the American Association for Cancer Research | ||
| Radiotherapy 70 Gray | Retrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma. | Veterinary and comparative oncology | ||
| Radiotherapy 70 Gray | Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer. | The Prostate | ||
| Cisplatin 100 mg/m^2 | Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. | Lancet (London, England) | ||
| Cisplatin 100 mg/m^2 | Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||
| Cisplatin 100 mg/m^2 | Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212. | ESMO open | ||
| Telcagepant 280 mg | Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. | Headache | ||
| Telcagepant 140 mg | Randomized, controlled trial of telcagepant over four migraine attacks. | Cephalalgia : an international journal of headache | ||
| Telcagepant | Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. | Neurology | ||
| Supportive care measures | POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management. | American journal of hematology | ||
| Supportive care measures | Nuances of Perioperative Therapy in Gingivobuccal Cancers. | Oral and maxillofacial surgery clinics of North America | ||
| Supportive care measures | Targeting the virus-host interface for the development of therapeutics against filoviruses. | Current opinion in virology | ||
| Rescue Medication | Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. | Lancet (London, England) | ||
| Rescue Medication | Living with Dravet syndrome: quality of life and caregiver burden among family caregivers in Europe. Results from the QoL4DRAVET study. | Epilepsy & behavior : E&B | ||
| Rescue Medication | Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. | The Journal of dermatological treatment | ||
| corticosteroid | Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT study. | Pulmonology | ||
| corticosteroid | Comment on: 'Ultrasound-guided injection strategies for lateral epicondylitis-a multicenter randomized comparison of corticosteroid, platelet-rich plasma, and ozone'. | Future science OA | ||
| corticosteroid | Implantable starch-based extrudates for controlled release of corticosteroids. | International journal of pharmaceutics: X | ||
| Rituximab biosimilar | A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy. | BMC pharmacology & toxicology | ||
| Rituximab biosimilar | Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center. | Clinics (Sao Paulo, Brazil) | ||
| Rituximab biosimilar | Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare. | Journal of medical economics | ||
| Belzutifan | Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer metastasis reviews | ||
| Belzutifan | HIF-2α/TRIB3/PARP1 axis promotes progression by orchestrating DNA repair in clear cell renal cell carcinoma. | Biochimica et biophysica acta. Molecular basis of disease | ||
| olaparib | Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K/AKT/mTOR signaling pathway. | Bioorganic & medicinal chemistry | ||
| Prednisone acetate | Oral AA amyloidosis with granulomatous cheilitis: a case report and literature review. | Clinical rheumatology | ||
| Prednisone acetate | [Ameliorative effects and mechanisms of Buyang Huanwu Decoction and its different ethanol elution fractions on pulmonary fibrosis model rats]. | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica | ||
| Prednisone acetate | E-cigarette or vaping product use-associated lung injury without pulmonary symptoms: A case report and literature review. | Medicine | ||
| Abiraterone acetate | Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer. | JAMA oncology | ||
| Abiraterone acetate | Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | ||
| Abiraterone acetate | Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy. | Cancer biology & therapy | ||
| Hydrocortisone | Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults. | Stress (Amsterdam, Netherlands) | ||
| Hydrocortisone | The impact of (poly)phenol-rich sugarcane extract intervention on markers of gastrointestinal integrity and systemic inflammation in response to exertional-heat stress. | Journal of the International Society of Sports Nutrition | ||
| Hydrocortisone | The association between pubertal timing and diurnal cortisol activity in middle adolescence. | Stress (Amsterdam, Netherlands) | ||
| Fludrocortisone acetate | Coenzyme Q alleviates oxidative stress, inflammation and fibrosis via activation of TGFβ1/TNF-α in FCA-Salt hypertensive rats. | Archives of biochemistry and biophysics | ||
| Fludrocortisone acetate | Process optimization of hot-melt extruded filaments for FDM 3D printing of personalized low-dose fludrocortisone acetate oral dosage forms. | International journal of pharmaceutics | ||
| Fludrocortisone acetate | Feline hypoadrenocorticism: Emerging insights into clinical features, diagnosis, and treatment. | Schweizer Archiv fur Tierheilkunde | ||
| Opevesostat | Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. | Future oncology (London, England) | ||
| Opevesostat | Design, synthesis, and biological evaluation of cytochrome P450 CYP11A1 inhibitors. | Bioorganic & medicinal chemistry letters | ||
| Irinotecan | Corrigendum to 'Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells' [Biomaterials 72 (2015) 17043]. | Biomaterials | ||
| Irinotecan | In depth study on the mechanism of Xiao-Chai-Hu-Tang in ameliorating irinotecan-induced intestinal toxicity and enhancing antitumor immunity via intestinal microbiota and fecal metabolomics. | Journal of pharmaceutical and biomedical analysis | ||
| MK-1084 | From KRAS to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design. | Journal of medicinal chemistry | ||
| MK-1084 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | ||
| Sacituzumab Tirumotecan | Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis. | Frontiers in immunology | ||
| Sacituzumab Tirumotecan | Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | ||
| Sacituzumab Tirumotecan | TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. | Future oncology (London, England) | ||
| Nab-paclitaxel | Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. | Advances in radiation oncology | ||
| Nab-paclitaxel | Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report. | Human vaccines & immunotherapeutics | ||
| Nab-paclitaxel | Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients. | Journal of medical economics | ||
| 5-Fluorouracil (5-FU) | Exosome-like nanoparticles derived from co-decoction enhance oral bioavailability and provide synergistic efficacy and reduced toxicity in combination with 5-fluorouracil for lung cancer therapy. | International journal of pharmaceutics: X | ||
| Capecitabine | Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients. | Pakistan journal of pharmaceutical sciences | ||
| Capecitabine | Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report. | The Pan African medical journal | ||
| Docetaxel | Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. | Journal of enzyme inhibition and medicinal chemistry | ||
| Docetaxel | Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective. | Journal of medical economics | ||
| Docetaxel | Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. | Cancer biology & therapy | ||
| MK-4830 | A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report. | SAGE open medical case reports | ||
| ATRA | All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. | International immunopharmacology | ||
| ATRA | Naja atra SVPLA upregulates hexokinase 2-driven macrophage M1 polarization via the cGAS-STING signaling activation. | Toxicon : official journal of the International Society on Toxinology | ||
| ATRA | Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review. | Annals of medicine | ||
| Vibostolimab | Beyond empiric checkpoint escalation: Insights from KEYVIBE-010. | Med (New York, N.Y.) | ||
| Lenvatinib | Integrative multi-omics profiling reveals DRG1 promotes hepatocellular carcinoma via c-Myc phosphorylation and facilitates lenvatinib resistance. | Cellular signalling | ||
| Lenvatinib | Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia. | Journal of medical economics | ||
| Lenvatinib | ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma. | Cancer biology & therapy | ||
| liposomal doxorubicin | Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. | ACS nano | ||
| liposomal doxorubicin | Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | ||
| liposomal doxorubicin | Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors. | Drug delivery | ||
| Doxorubicin | Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. | Drug delivery | ||
| Doxorubicin | Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy. | Bioactive materials | ||
| Doxorubicin | Integrating spectrum-effect relationship, network pharmacology and multi-omics to decipher the mechanism of Cybister chinensis Motschulsky against chronic kidney disease. | Journal of ethnopharmacology | ||
| paclitaxel | A phytotherapeutic candidate for neuropathic pain: Helicteres ovata (Lam.) extract shows antinociceptive effects and favorable acute toxicity profile. | Journal of ethnopharmacology | ||
| carboplatin | Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. | Cancer biology & therapy | ||
| carboplatin | A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology | ||
| carboplatin | Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas. | The veterinary quarterly | ||
| MK-1045 | Phytoconstituents and Bioactivity of Plants of the Genus L. (Rosaceae): A Review. | International journal of molecular sciences | ||
| corticosteroid | Prediction of Prolonged Length of Hospital Stay in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: An Interpretable Machine Learning Tool. | Journal of clinical medicine | ||
| MK-6194 | Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. | ImmunoHorizons | ||
| liposomal doxorubicin | Radiolabeling of clinically approved nanomedicine carriers: lessons from albumin- and liposome-based systems for biomaterial design and translational imaging. | Nanomedicine (London, England) | ||
| liposomal doxorubicin | Feasibility and Safety of Repeated Intraperitoneal Platinum and Pegylated Liposomal Doxorubicin for First Recurrent Ovarian Cancer: A Preliminary Retrospective Comparative Study. | Cancers | ||
| Doxorubicin | RETRACTION: Doxorubicin-loaded methoxy-intercalated kaolinite as a repackaging of doxorubicin for an enhanced breast cancer treatment:andinvestigation (2025 36 025101). | Nanotechnology | ||
| Doxorubicin | Therapeutic Efficacy of Metronomic Doxorubicin and Low Dose of Gamma Radiation on Breast Cancer Model. | Cell biochemistry and function | ||
| 5-Fluorouracil (5-FU) | Betulin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice. | Nutrients | ||
| 5-Fluorouracil (5-FU) | Resveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. | International journal of molecular sciences | ||
| Levoleucovorin | Leucovorin Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. | Anticancer research | ||
| Capecitabine | Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States. | Breast cancer research and treatment | ||
| Capecitabine | Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal. | Cancers | ||
| Sacituzumab Tirumotecan (sac-TMT) | Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer. | Translational lung cancer research | ||
| Docetaxel | Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. | Breast (Edinburgh, Scotland) | ||
| Docetaxel | UNCX/SIN3A-Mediated H4K8 decrotonylation suppresses FOXO3 to drive TNBC progression and docetaxel resistance. | Cellular signalling | ||
| MK-4830 | KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. | Future oncology (London, England) | ||
| MK-4830 | Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient. | Frontiers in pharmacology | ||
| ATRA | DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy. | BMC cancer | ||
| ATRA | Systemic administration of all-trans retinoic acid modulated circulating immune cells but failed to improve healing in a preclinical model of musculoskeletal trauma. | Frontiers in immunology | ||
| Vibostolimab | Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C. | ESMO open | ||
| Vibostolimab | No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity. | Cancer | ||
| Quavonlimab | LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. | Future oncology (London, England) | ||
| Quavonlimab | Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. | Annals of oncology : official journal of the European Society for Medical Oncology | ||
| Lenvatinib | LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62-Keap1-Nrf2 pathway. | Cancer drug resistance (Alhambra, Calif.) | ||
| Lenvatinib | Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. | Lancet (London, England) | ||
| paclitaxel | DHA Alone, EPA + DHA, EPA + DHA + GLA, and EPA + DHA with or Without Vitamin D During Chemotherapy in Women with Breast Cancer: An Intervention- and Outcome-Stratified Systematic Review. | Nutrients | ||
| paclitaxel | Case Report: Synchronous Esophageal Squamous Cell Carcinoma and Gastric Cardia Adenocarcinoma with Hepatoid Differentiation After Neoadjuvant Chemoimmunotherapy. | Journal of clinical medicine | ||
| carboplatin | Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). | PloS one | ||
| carboplatin | Sequential development of isolated ACTH deficiency and fulminant type 1 diabetes as delayed immune-related endocrine adverse events. | BMJ case reports | ||
| Telcagepant 280 mg | Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. | Headache | ||
| Telcagepant 140 mg | Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. | Neurology | ||
| Telcagepant 140 mg | Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. | Cephalalgia : an international journal of headache | ||
| Telcagepant | Blocking the CGRP Receptor: Differences across Human Vascular Beds. | Pharmaceuticals (Basel, Switzerland) | ||
| Telcagepant | CGRP receptor antagonists (gepants). | Handbook of clinical neurology | ||
| Lenvatinib | T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy. | Science advances | ||
| Lenvatinib | Plant-derived natural products against hepatocellular carcinoma: chemical diversity, mechanisms of action, and organ-based classification. | Natural product research | ||
| carboplatin | Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? | Future science OA | ||
| carboplatin | DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation. | Frontiers in pharmacology | ||
| Doxorubicin | A clinical data- and AI-supported engineered fusion vesicle system for enhanced tumor-targeted drug delivery and immunochemotherapeutic synergy. | Journal of controlled release : official journal of the Controlled Release Society | ||
| paclitaxel | A bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β1 (SHR1701) enhanced preclinical antitumor activity in oral squamous cell carcinoma. | Oral oncology | ||
| Doxorubicin | Successful Sequential Multimodal Therapy for Lingual Rhabdomyosarcoma in a Young Adult: Case Report. | Case reports in oncological medicine | ||
| Doxorubicin | Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin. | Medical oncology (Northwood, London, England) | ||
| paclitaxel | Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. | Biomolecules & biomedicine | ||
| carboplatin | An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. | Expert review of anticancer therapy | ||
| carboplatin | Exploding retinoblastoma- Management of spontaneous scleral rupture in an infant with bilateral retinoblastoma. | Retinal cases & brief reports | ||
| liposomal doxorubicin | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin. | Journal of liposome research | ||
| liposomal doxorubicin | Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers. | Annals of hematology | ||
| Doxorubicin | Evaluation of the protective effects of Artemisia dracunculus L. against doxorubicin-induced chronic cardio-toxicity in rat. | Fitoterapia | ||
| Doxorubicin | Synchronous rectal cancer and extranodal NK/T-cell lymphoma, nasal type: A case report. | Medicine | ||
| paclitaxel | Photothermal and photo-oxidation mediated release of lipophilic paclitaxel from liposomes: from formulation to in vitro efficacy and molecular dynamics simulations? | International journal of pharmaceutics | ||
| paclitaxel | Paclitaxel's Broken Promise for Dialysis Access: The ABISS Trial. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery | ||
| carboplatin | Performance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. | Cancer treatment and research communications | ||
| carboplatin | Integrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer. | Chinese journal of integrative medicine | ||
| carboplatin | Efficacy of poloxamer Р188 in restoring the metabolic profile in myelosuppression: a non-invasive nuclear magnetic resonance spectroscopy study. | Biomeditsinskaia khimiia | ||
| carboplatin | Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. | JAMA network open | ||
| liposomal doxorubicin | Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||
| carboplatin | Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review. | The American journal of case reports | ||
| paclitaxel | Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment. | BMC cancer | ||
| paclitaxel | Repurposed anticancer drugs disrupt cancer-like traits of Theileria annulata and suppress Leishmania donovani. | Cell communication and signaling : CCS | ||
| liposomal doxorubicin | A Novel Capillary Electrophoresis Capacitively Coupled Contactless Conductivity Detection (CE‑CD) Method for Quantification of Ionic Excipients in Doxorubicin HCl Liposome Injection. | ACS omega | ||
| liposomal doxorubicin | Dexamethasone for PEGylated liposomal doxorubicin cutaneous toxicity: Denominators, regimen identity, and implementation. | Journal of controlled release : official journal of the Controlled Release Society | ||
| Doxorubicin | Sustainable gold nanoparticles using Jania rubens, targeted therapeutic potential in prostate cancer and mechanistic insights via GO/KEGG pathway analysis. | Scientific reports | ||
| paclitaxel | Therapeutic Effect of Parthenolide on Paclitaxel-Induced Cardiotoxicity in Rats. | Journal of cellular biochemistry | ||
| paclitaxel | ROS-Activatable "off-on" Fluorescent Prodrug Loaded Micelles for Targeted Therapy and in Situ Imaging of Breast Cancer Cells. | International journal of pharmaceutics: X | ||
| carboplatin | Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | ||
| carboplatin | Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report. | Cureus | ||
| paclitaxel | Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. | BMJ oncology | ||
| paclitaxel | Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms. | Naunyn-Schmiedeberg's archives of pharmacology | ||
| carboplatin | Severe Inflammatory Cystitis and Ureteritis Following Neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) Therapy in HER2-Positive Breast Cancer: A Case Report and Literature Review. | Cureus | ||
| carboplatin | Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). | JAMA oncology | ||
| paclitaxel | Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | ||
| paclitaxel | Paclitaxel and B7-H6 knockdown inhibit HepG2 hepatocellular carcinoma cell viability and migration, while enhancing apoptosis and cell cycle arrest. | Molecular biology reports |